Boston Scientific (NYSE: BSX) reported Q1 EPS of $0.80, $0.01 better than the analyst estimate of $0.79. Revenue for the quarter came in at $5.2 billion versus the consensus estimate of $5.17 billion.

GUIDANCE:

Boston Scientific sees FY2026 EPS of $3.34-$3.41, versus the consensus of $3.45.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.